pharmacoproteomics
Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr Pharm Des. 2007;13(3):263-70. PMID: 17313360
Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Technology insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006 May;3(5):256-68. PMID: 16683004
Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond). 2005 May;108(5):369-83. PMID: 15831087
Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam Clin Pharmacol. 2004 Aug;18(4):413-22. PMID: 15312147
Loni L, De Braud F, Zinzani PL, Danesi R. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44 Suppl 3:S115-22. PMID: 15202534
Di Paolo A, Danesi R, Del Tacca M. Pharmacogenetics of neoplastic diseases: new trends. Pharmacol Res. 2004 Apr;49(4):331-42. PMID: 15202512
Kley N, Ivanov I, Meier-Ewert S. Genomics and proteomics tools for compound mode-of-action studies in drug discovery. Pharmacogenomics. 2004 Jun;5(4):395-404. PMID: 15165175
Jain KK. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics. 2004 Apr;5(3):331-6. PMID: 15102547
Witzmann FA, Grant RA. Pharmacoproteomics in drug development.
Pharmacogenomics J. 2003;3(2):69-76. PMID: 12746732
Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers. 2002 Jul-Aug;7(4):269-90. PMID: 12171755